TY - JOUR
T1 - Autophagy as a therapeutic target in cardiovascular disease
AU - Nemchenko, Andriy
AU - Chiong, Mario
AU - Turer, Aslan
AU - Lavandero, Sergio
AU - Hill, Joseph A.
N1 - Funding Information:
This work was supported by grants from the NIH ( HL-075173 , JAH; HL-080144 , JAH; HL-090842 , JAH), AHA ( 0640084N , JAH), ADA ( 7-08-MN-21-ADA , JAH), the AHA-Jon Holden DeHaan Foundation ( 0970518N , JAH), and the Fondo Nacional de Desarrollo Cientifico y Tecnologico, Chile ( FONDECYT 1080436 , SL; FONDAP 15010006 , SL). SL is on a sabbatical leave at the University of Texas Southwestern Medical Center, Dallas, Texas, USA.
PY - 2011/10
Y1 - 2011/10
N2 - The epidemic of heart failure continues apace, and development of novel therapies with clinical efficacy has lagged. Now, important insights into the molecular circuitry of cardiovascular autophagy have raised the prospect that this cellular pathway of protein quality control may be a target of clinical relevance. Whereas basal levels of autophagy are required for cell survival, excessive levels - or perhaps distinct forms of autophagic flux - contribute to disease pathogenesis. Our challenge will be to distinguish mechanisms that drive adaptive versus maladaptive autophagy and to manipulate those pathways for therapeutic gain. Recent evidence suggests this may be possible. Here, we review the fundamental biology of autophagy and its role in a variety of forms of cardiovascular disease. We discuss ways in which this evolutionarily conserved catabolic mechanism can be manipulated, discuss studies presently underway in heart disease, and provide our perspective on where this exciting field may lead in the future. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."
AB - The epidemic of heart failure continues apace, and development of novel therapies with clinical efficacy has lagged. Now, important insights into the molecular circuitry of cardiovascular autophagy have raised the prospect that this cellular pathway of protein quality control may be a target of clinical relevance. Whereas basal levels of autophagy are required for cell survival, excessive levels - or perhaps distinct forms of autophagic flux - contribute to disease pathogenesis. Our challenge will be to distinguish mechanisms that drive adaptive versus maladaptive autophagy and to manipulate those pathways for therapeutic gain. Recent evidence suggests this may be possible. Here, we review the fundamental biology of autophagy and its role in a variety of forms of cardiovascular disease. We discuss ways in which this evolutionarily conserved catabolic mechanism can be manipulated, discuss studies presently underway in heart disease, and provide our perspective on where this exciting field may lead in the future. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."
UR - http://www.scopus.com/inward/record.url?scp=80052801111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052801111&partnerID=8YFLogxK
U2 - 10.1016/j.yjmcc.2011.06.010
DO - 10.1016/j.yjmcc.2011.06.010
M3 - Review article
C2 - 21723289
AN - SCOPUS:80052801111
SN - 0022-2828
VL - 51
SP - 584
EP - 593
JO - Journal of Molecular and Cellular Cardiology
JF - Journal of Molecular and Cellular Cardiology
IS - 4
ER -